After an extensive search for a chief of Cleveland Clinic’s Bariatric and Metabolic Institute, Ali Aminian, MD, was named to the leadership position.
A large matched-cohort study in patients with type 2 diabetes and obesity finds that metabolic surgery confers significant improvements in all prespecified events plus marked reductions in weight, HbA1c, and use of diabetes and cardiovascular medications.
Patients can expect to lose additional weight on canagliflozin after weight loss plateau following metabolic surgery, according to a recently published randomized clinical trial. Endocrinologist Sangeeta Kashyap, MD, explains.
Subanalysis of STAMPEDE trial data suggests the percentage of weight loss in the first year following surgery may be more important to diabetes management than weight fluctuations in the first five years.